← NEUROCRINE BIOSCIENCES INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($141.1m) | ($142.5m) | $21.1m | $37.0m | $407.3m | $89.6m | $154.5m | $249.7m | $341.3m | $478.6m | — | |
| Depreciation and amortization | $1.5m | $2.4m | $4.0m | $7.5m | $8.6m | $10.9m | $15.1m | $17.8m | $23.5m | $26.0m | $47.3m | |
| Depreciation | $1.5m | $2.4m | $4.0m | $7.5m | $8.6m | $10.9m | $15.1m | $17.8m | $23.5m | $26.0m | $28.7m | |
| Amortization of Debt Issuance Costs | — | $848k | $1.3m | $1.4m | $1.4m | $1.1m | $1.2m | $700k | — | — | — | |
| Amortization of Intangible Assets | — | — | — | — | $0 | $0 | $500k | $3.5m | $3.6m | $4.1m | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | ($310.7m) | $5.5m | $22.0m | ($60.7m) | ($123.0m) | $164.2m | $130.1m | |
| Share-based Payment Arrangement, Noncash Expense | $28.5m | $42.5m | $58.1m | $75.3m | $100.0m | $134.2m | $173.1m | $194.3m | $195.5m | $217.9m | $234.5m | |
| Share-based Payment Arrangement, Expense | $28.5m | $42.5m | $58.1m | $75.3m | $100.0m | $134.2m | $173.1m | $194.3m | $195.5m | $217.9m | $234.5m | |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss | — | — | — | $0 | — | — | — | — | — | — | — | |
| Operating Lease, Impairment Loss | — | — | — | — | — | — | — | — | — | $700k | — | |
| Nonoperating Income (Expense) | $6.3m | ($11.2m) | ($15.1m) | ($25.7m) | ($56.3m) | ($1.1m) | ($35.1m) | $81.2m | ($84.5m) | $86.3m | — | |
| Other Nonoperating Income (Expense) | $13k | ($20k) | — | — | — | — | — | — | — | — | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | $31.1m | $25.1m | $69.2m | $30.5m | $28.4m | $162.2m | $89.3m | $39.8m | $210.5m | ($259.6m) | |
| Increase (Decrease) in Inventories | — | $1.0m | $3.5m | $6.4m | $10.7m | $2.5m | $2.6m | ($5.4m) | $19.1m | $15.3m | ($17.9m) | |
| Net Cash Provided by (Used in) Operating Activities | ($106.2m) |
($94.3m)
+11.16%
|
$101.4m
+207.46%
|
$152.1m
+50.01%
|
$228.5m
+50.28%
|
$256.5m
+12.25%
|
$339.4m
+32.32%
|
$389.9m
+14.88%
|
$595.4m
+52.71%
|
$782.7m
+31.46%
|
$898.1m
+14.74%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $4.1m | $6.9m | $24.8m | $14.7m | $10.9m | $23.4m | $16.5m | $28.3m | $38.2m | $34.0m | ($27.7m) | |
| Marketable Securities, Unrealized Gain (Loss) | — | — | — | $3.3m | $400k | ($3.5m) | — | — | — | — | — | |
| Payments to Acquire Investments | $298.8m | $583.4m | $546.0m | — | — | — | — | — | — | — | ($1.6b) | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | — | — | — | — | — | $42.7m | $0 | $0 | — | $0 | |
| Net Cash Provided by (Used in) Investing Activities | — | ($251.3m) | ($242.9m) | ($211.1m) | $4.1m | ($130.2m) | ($177.1m) | ($467.1m) | ($126.8m) | ($264.4m) | ($891.2m) | |
| Cash flows from financing activities: | ||||||||||||
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | ($18.4m) | $0 | ($70.0m) | $0 | ($2.2m) | — | — | |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | — | — | $300.0m | $167.7m | — | |
| Proceeds from Issuance of Common Stock | $2.4m | $13.9m | $29.5m | $27.3m | $29.1m | $27.5m | $44.7m | $65.3m | $122.1m | $129.4m | — | |
| Net Cash Provided by (Used in) Financing Activities | $2.4m |
$516.6m
+21516.99%
|
$29.5m
-94.28%
|
$27.3m
-7.51%
|
($157.8m)
-677.75%
|
$27.4m
+117.36%
|
($234.3m)
-955.11%
|
$65.3m
+127.87%
|
($486.7m)
-845.33%
|
($38.3m)
+92.13%
|
$60.2m
+257.18%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | ($112.0m) | ($31.7m) | $74.8m | $153.7m | ($73.3m) | ($11.6m) | ($18.1m) | $480.0m | $339.1m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $9.2m | $171.1m | $147.2m | $115.5m | $190.3m | $344.0m | $270.7m | $259.1m | $241.0m | $721.0m | $339.1m | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | $0 | $0 | ($1.3m) | $300k | $0 | $0 | ($200k) | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $2.4m | $13.9m | $29.5m | $27.3m | $23.5m | $20.7m | $37.0m | $55.5m | $110.8m | $115.5m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $0 | $6.2m | $11.6m | $11.6m | $11.6m | $8.6m | $6.6m | $3.8m | $1.6m | $0 | — | |
| Income Taxes Paid, Net | $0 | $0 | $0 | $507k | $15.3m | $5.1m | $14.4m | $51.5m | $217.5m | $81.4m | — | |
| Additional Financial Items | ||||||||||||
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | ($13.0m) | ($17.7m) | $20.9m | $30.8m | $28.4m | ($37.1m) | ($4.0m) | — | |
| Gain (Loss) on Disposition of Assets for Financial Service Operations | $3.4m | $2.1m | $760k | — | — | — | — | — | — | — | — | |
| General and Administrative Expense | $68.1m | — | — | — | — | — | — | — | — | — | — | |
| Goodwill | — | — | — | — | — | — | $5.4m | $5.8m | $5.7m | — | $700k | |
| Income Tax Expense (Benefit) | $0 | $0 | $730k | $9.5m | ($300.6m) | $11.8m | $59.4m | $82.4m | $144.7m | $226.8m | — | |
| Investment Income, Interest | $2.8m | — | — | — | — | — | — | — | — | — | — | |
| Operating Expenses | $162.4m | $293.0m | $414.3m | $715.8m | $882.9m | $1.0b | — | — | — | — | — | |
| Realized Investment Gains (Losses) | $0 | — | — | — | — | — | — | — | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.